Literature DB >> 8622505

Association between schizophrenia and T102C polymorphism of the 5-hydroxytryptamine type 2a-receptor gene. European Multicentre Association Study of Schizophrenia (EMASS) Group.

J Williams1, G Spurlock, P McGuffin, J Mallet, M M Nöthen, M Gill, H Aschauer, P O Nylander, F Macciardi, M J Owen.   

Abstract

BACKGROUND: An association between schizophrenia and the T102C polymorphism of the gene for 5-hydroxytryptamine type 2a (5-HT2a) receptor has been reported; the proportion of allele 2 of this polymorphism is higher than expected among schizophrenic patients. We looked for an association between schizophrenia and this variant of the 5-HT2a-receptor gene in a large multicentre study.
METHODS: Seven countries recruited 1210 participants: 571 white schizophrenic patients and 639 ethnically matched controls. All patients had a diagnosis of schizophrenia or schizoaffective disorder. High-molecular-weight DNA was isolated from lymphocytes. PCR amplification and restriction enzyme digestion was used to examine sequence variation of the 5-HT2a-receptor gene. Genotypes 1/1, 1/2, and 2/2 were assigned. Woolf's method was used to look for an association between schizophrenia and allele 2 and the 2/2 genotype.
FINDINGS: We found a significant overall association between schizophrenia and allele 2 with an odds ratio of 1.3 (95% Cl 1.1-1.53, p = 0.003). No evidence for heterogeneity was observed between samples. We found a highly significant excess of the 1-2/2-2 genotypes in schizophrenia (p = 0.008) with a relative risk of 1.7 (1.22-2.36) and an attributable fraction of 0.35.
INTERPRETATION: Our findings suggest that the gene for 5-HT2a-receptor, or a locus in linkage disequilibrium with it, confers susceptibility to schizophrenia. Allele 2 is common in the population and it is, therefore, likely that this variant, or a nearby polymorphism, may affect a significant proportion of schizophrenic patients.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8622505     DOI: 10.1016/s0140-6736(96)90939-3

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  31 in total

Review 1.  Candidate-gene association studies of schizophrenia.

Authors:  M C O'Donovan; M J Owen
Journal:  Am J Hum Genet       Date:  1999-09       Impact factor: 11.025

Review 2.  Genetic analyses of schizophrenia.

Authors:  C N Pato; K M Schindler; M T Pato
Journal:  Curr Psychiatry Rep       Date:  2000-04       Impact factor: 5.285

Review 3.  Genetics of schizophrenia and the new millennium: progress and pitfalls.

Authors:  M Baron
Journal:  Am J Hum Genet       Date:  2001-01-17       Impact factor: 11.025

Review 4.  Recent advances in the genetics of schizophrenia.

Authors:  D M Waterwort; A S Bassett; L M Brzustowicz
Journal:  Cell Mol Life Sci       Date:  2002-02       Impact factor: 9.261

5.  Effects of population structure and sex on association between serotonin receptors and Drosophila heart rate.

Authors:  Naruo Nikoh; April Duty; Greg Gibson
Journal:  Genetics       Date:  2004-12       Impact factor: 4.562

6.  Selective serotonin 5-HT2A receptor antagonist EMD 281014 improves delayed matching performance in young and aged rhesus monkeys.

Authors:  Alvin V Terry; Jerry J Buccafusco; Gerd D Bartoszyk
Journal:  Psychopharmacology (Berl)       Date:  2004-12-24       Impact factor: 4.530

7.  Genetic association studies in psychiatry. Are we putting the cart before the horse?

Authors:  P D Hrdina
Journal:  J Psychiatry Neurosci       Date:  1998-09       Impact factor: 6.186

Review 8.  The molecular genetics of schizophrenia.

Authors:  K C Murphy; A G Cardno; P McGuffin
Journal:  J Mol Neurosci       Date:  1996       Impact factor: 3.444

Review 9.  G protein-coupled receptors in major psychiatric disorders.

Authors:  Lisa A Catapano; Husseini K Manji
Journal:  Biochim Biophys Acta       Date:  2006-10-03

10.  Modulation of neuronal excitability by serotonin-NMDA interactions in prefrontal cortex.

Authors:  Ping Zhong; Eunice Y Yuen; Zhen Yan
Journal:  Mol Cell Neurosci       Date:  2008-03-25       Impact factor: 4.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.